Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress
Alnylam reported Q3 2026 net product revenues of $1,292 million, up 52% year-over-year, led by AMVUTTRA at $1,130 million (+65%) on strong U.S. ATTR-CM demand. Total revenues rose 17% to $1,458 million; GAAP net income of $2.17 billion was inflated by a $1.9 billion non-cash tax valuation-allowance release, with non-GAAP diluted EPS of $16.26 up 410%. The company reiterated its FY2026 guidance of $4.7-$5.1 billion in net product revenues and expanded the TRITON-CM Phase 3 enrollment target to 2,250 patients, still targeting a nucresiran ATTR-CM launch by 2030.
Key figures
- Eps
- 15.72
- Revenue
- 1458086000
- Guidance
- FY2026 reiterated: total net product revenues $4,700M-$5,100M; total TTR $4,200M-$4,500M; total Rare $500M-$600M; collaborations and royalties $575M-$625M; non-GAAP R&D and SG&A $2,700M-$2,800M
- Revenue Yoy
- 17%
- Ttr yoy
- 59%
- Tax benefit
- $1.9 billion
- Ttr revenue
- 1149959000
- Amvuttra yoy
- 65%
- Gaap net income
- 2167335000
- Amvuttra revenue
- 1130363000
- Net product revenue
- 1291946000
- Nongaap diluted eps
- 16.26
- Net product revenue yoy
- 52%
- Triton cm enrollment target
- 2250
- Brezosiran csf mhtt reduction
- 60-64% at month 3 in highest dose group
- Cash and marketable securities
- $3.6 billion
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.